Mitrix bio

Mitrix Bio is a private, pre-clinical stage biotech founded in 2019 and based in San Francisco, focused on developing mitochondrial transplantation as a new therapeutic modality. The company's platform centers on the industrial-scale production of 'Mitlets'—vesicle-encased, young mitochondria—designed to supplement aged or dysfunctional cells in organs like the brain, retina, and immune system. While still in the research and development phase, Mitrix aims to address a broad spectrum of age-related diseases by targeting the root cause of cellular energy decline. The company is backed by investors including R42 Capital and LongevityTech Fund.

Platform for industrial-scale production of young, healthy mitochondria ('Mitlets') encapsulated in targeted extracellular vesicles for transplantation to treat diseases of mitochondrial dysfunction.

Mitrix Bio operates in a nascent field with few direct competitors focused on exogenous mitochondrial transplantation as a therapeutic product. Indirect competition comes from other geroscience approaches (senolytics, mTOR inhibitors) and companies developing mitochondrial-targeted small molecules or gene therapies. Its primary competitive edge is its focus on scalable manufacturing of the therapeutic agent itself.